399 related articles for article (PubMed ID: 16979814)
21. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
Wright PJ
Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
[TBL] [Abstract][Full Text] [Related]
22. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
23. Erectile dysfunction in aging men: testosterone role in therapeutic protocols.
Caretta N; Ferlin A; Palego PF; Foresta C
J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):108-11. PubMed ID: 16760637
[TBL] [Abstract][Full Text] [Related]
24. Recent insights into androgen action on the anatomical and physiological substrate of penile erection.
Gooren LJ; Saad F
Asian J Androl; 2006 Jan; 8(1):3-9. PubMed ID: 16372114
[TBL] [Abstract][Full Text] [Related]
25. The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men.
Matic H; McCabe MP
Int J Impot Res; 2007; 19(4):418-23. PubMed ID: 17538638
[TBL] [Abstract][Full Text] [Related]
26. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum.
Zhang XH; Morelli A; Luconi M; Vignozzi L; Filippi S; Marini M; Vannelli GB; Mancina R; Forti G; Maggi M
Eur Urol; 2005 Mar; 47(3):409-16; discussion 416. PubMed ID: 15716209
[TBL] [Abstract][Full Text] [Related]
27. Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow.
Foresta C; Caretta N; Lana A; De Toni L; Biagioli A; Vinanzi C; Ferlin A
Eur Urol; 2007 May; 51(5):1411-7; discussion 1417-9. PubMed ID: 17034932
[TBL] [Abstract][Full Text] [Related]
28. Testosterone therapy in erectile dysfunction and hypogonadism.
Shabsigh R
J Sex Med; 2005 Nov; 2(6):785-92. PubMed ID: 16422803
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
de Tejada IS
Int J Impot Res; 2004 Jun; 16 Suppl 1():S40-2. PubMed ID: 15224136
[TBL] [Abstract][Full Text] [Related]
30. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone.
Hwang TI; Chen HE; Tsai TF; Lin YC
Int J Impot Res; 2006; 18(4):400-4. PubMed ID: 16395321
[TBL] [Abstract][Full Text] [Related]
31. PDE5 inhibitors beyond erectile dysfunction.
Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
[TBL] [Abstract][Full Text] [Related]
32. Rationale for androgens and erectile dysfunction in 2006.
Roumeguère T
Eur Urol; 2006 Nov; 50(5):898-900. PubMed ID: 16893603
[No Abstract] [Full Text] [Related]
33. Testosterone and erectile dysfunction.
Yassin AA; Saad F
J Androl; 2008; 29(6):593-604. PubMed ID: 18641415
[TBL] [Abstract][Full Text] [Related]
34. [Novel indications for phosphodiesterase type 5 inhibitors].
Rosenkranz S; Caglayan E; Erdmann E
Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
[TBL] [Abstract][Full Text] [Related]
35. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Patel MD; Katz SD
Am J Cardiol; 2005 Dec; 96(12B):47M-51M. PubMed ID: 16387567
[TBL] [Abstract][Full Text] [Related]
36. Significance of hypogonadism in erectile dysfunction.
Buvat J; Bou Jaoudé G
World J Urol; 2006 Dec; 24(6):657-67. PubMed ID: 17082935
[TBL] [Abstract][Full Text] [Related]
37. Commentary on adjunctive use of testosterone gel with sildenafil for erectile dysfunction.
Morales A
J Urol; 2008 May; 179(5 Suppl):S103. PubMed ID: 18405738
[No Abstract] [Full Text] [Related]
38. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
39. Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors.
Fleshner N; Harvey M; Adomat H; Wood C; Eberding A; Hersey K; Guns E
J Urol; 2005 Aug; 174(2):636-41; discussion 641; quiz 801. PubMed ID: 16006928
[TBL] [Abstract][Full Text] [Related]
40. Erectile dysfunction in patients with coronary artery disease.
Kloner R; Padma-Nathan H
Int J Impot Res; 2005; 17(3):209-15. PubMed ID: 15729374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
